AstraZeneca plc (LON:AZN) today announced that it has received marketing authorisation from China’s National Medical Products Administration for Tagrisso as a 1st-line treatment for adults with locally-advanced or metastatic non-small..

Brilinta reduced the risk of cardiovascular events in patients with coronary artery disease and type-2 diabetes in Phase III THEMIS trial. Additionally, Brilinta showed a more favourable clinical benefit in..

AstraZeneca plc (LON:AZN) today announced detailed results from the landmark Phase III DAPA-HF trial that showed Farxiga on top of standard of care reduced both the incidence of cardiovascular death..

AstraZeneca plc (LON: AZN) today announced that the Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of systemic lupus erythematosus (SLE), met its primary..

AstraZeneca plc (LON:AZN) today announced positive results from the Phase III ETHOS trial for triple-combination therapy Breztri Aerosphere, formerly PT010, in patients with moderate to very severe chronic obstructive pulmonary..

AstraZeneca plc (LON:AZN) today announced that the US Food and Drug Administration has granted Orphan Drug Designation to Fasenra (benralizumab) for the treatment of eosinophilic oesophagitis (EoE). EoE is a..

AstraZeneca plc (LON:AZN) today announced that it has agreed to buy a US Food and Drug Administration Priority Review Voucher for a total cash consideration of $95m from a subsidiary..

AstraZeneca (LON: AZN) today announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorisation for roxadustat in China for the treatment of anaemia..

AstraZeneca plc (LON: AZN) today announced final overall survival results from the Phase III NEPTUNE trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) in combination with tremelimumab, an..

Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure DAPA-HF is the first heart failure outcomes trial with an SGLT2 inhibitor..

AstraZeneca plc (LON:AZN) today announced that, with effect from 1 September 2019, Michel Demaré is appointed as a Non-Executive Director and a member of the Audit Committee. Leif Johansson, Chairman..

AstraZeneca plc (LON:AZN) today announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation for Calquence as a monotherapy treatment for adult patients with chronic lymphocytic leukaemia,..

AstraZeneca plc (LON:AZN) and MSD Inc., known as Merck & Co., Inc. inside the US and Canada, today announced positive results from the Phase III PAOLA-1 trial in women with..

AstraZeneca plc (LON: AZN) today announced positive overall survival results from the Phase III FLAURA trial, a randomised, double-blinded, multi-centre trial of Tagrisso (osimertinib) in previously-untreated patients with locally-advanced or..

AstraZeneca plc (LON: AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced positive results from the Phase III..

AstraZeneca plc (LON:AZN) today announced that the European Commission has approved an update to the marketing authorisation for Forxiga to include positive cardiovascular outcomes and renal data from the Phase..

AstraZeneca plc (LON: AZN) today announced that the US Food and Drug Administration has issued a complete response letter regarding the supplemental New Drug Application for Farxiga (dapagliflozin) as an..

AstraZeneca (LON: AZN) has today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Imfinzi (durvalumab) for the treatment of small cell lung..

AstraZeneca plc (LON: AZN) has today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to add a self-administration option..

AstraZeneca plc (LON: AZN) has today announced positive overall survival results from the Phase III CASPIAN trial with Imfinzi in 1st-line extensive-stage small cell lung cancer, a disease with significant..